Roivant Sciences

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Retrieved on: 
Wednesday, July 5, 2023
LLP, Gilead Sciences, University, Switzerland, Kingston, Risk management, Queen's University at Kingston, Lyell, Labour law, Dechert, Classics, Employment, Organization, Acquisition, Patient, SAN, Roivant Sciences, Corporation, Growth, Information governance, Management, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D.
  • has joined the executive management team as Chief Business Officer.
  • In this newly created role, Mr. Lang will serve on Lyell’s executive committee and will be responsible for Lyell’s legal, compliance, human resources, alliance management and early commercialization teams.
  • He will also serve as Lyell’s Chief Legal Officer and Corporate Secretary.

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

Retrieved on: 
Monday, June 26, 2023
Webcast, Roivant Sciences, Cryptocurrency, Online shopping

ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provide business update.

Key Points: 
  • ET on Wednesday, June 28, 2023, to report its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provide business update.
  • To access the conference call by phone, please register online using this registration link .
  • The presentation and webcast details will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.
  • The archived webcast will be available on Roivant’s website after the conference call.

Health in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness Month

Retrieved on: 
Monday, June 26, 2023
Survivor, Endometriosis, Partnership, Boston University Chobanian & Avedisian School of Medicine, Obstetrics, Education, Boston Medical Center, Health equity, Woman, Human, Black, SMPA, Boston University School of Public Health, Patient, SAN, Roivant Sciences, Uterine fibroid, Disease, Gynaecology, Mortality, BRCA, Fibroid, MPH, Breast cancer, Therapy, Empowerment, Nursing, Health

NEW YORK and SAN MATEO, Calif., June 26, 2023 /PRNewswire/ -- Today, Health in Her HUE ("HIHH"), a company dedicated to connecting Black women and women of color to culturally competent and sensitive healthcare providers, announced an ongoing collaboration with Myovant Sciences Ltd. ("Myovant"), soon to be Sumitomo Pharma America, Inc. ("SMPA") as a result of the combination announced April 2023. The collaboration will kick-off with a fireside chat titled "Fighting Fibroids Together: A Candid Conversation Over Brunch," in New Orleans, Louisiana on July 1st, 2023 during the ESSENCE festival weekend. In acknowledgement of Fibroid Awareness Month, this event aims to support education and awareness efforts for historically underserved populations diagnosed with uterine fibroids.

Key Points: 
  • The collaboration will kick-off with a fireside chat titled "Fighting Fibroids Together: A Candid Conversation Over Brunch," in New Orleans, Louisiana on July 1st, 2023 during the ESSENCE festival weekend.
  • In acknowledgement of Fibroid Awareness Month, this event aims to support education and awareness efforts for historically underserved populations diagnosed with uterine fibroids.
  • The event will help launch HIHH's new Fibroids-focused Care Squad , which focuses on guiding participants toward a better understanding of fibroids as a health relevant condition and the possible linkage between fibroids and other health diagnoses.
  • With a wealth of experience in fibroids, endometriosis, and disparities in maternal morbidity and mortality, Dr. Noel is a leading voice in women's health and developed the content for the Fibroids-focused Care Squad.

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

Retrieved on: 
Thursday, June 22, 2023
IBD, Pharmacokinetics, EDT, Ulcerative colitis, ADAS, Patient, Webcast, Lance, Safety, Vaccine, Pharmaceutical industry, Roivant Sciences

TUSCANY-2 is a 56-week study in which the key efficacy analyses from the induction period comparing different doses of RVT-3101 against placebo were measured at week 14.

Key Points: 
  • TUSCANY-2 is a 56-week study in which the key efficacy analyses from the induction period comparing different doses of RVT-3101 against placebo were measured at week 14.
  • Key outcomes for the chronic period, in which all patients received RVT-3101, were measured at week 56.
  • Patients who received RVT-3101 in the induction period were preassigned to receive either the same or a lower dose in the chronic period.
  • Roivant reported positive data for the induction period of the study in January 2023.

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

Retrieved on: 
Wednesday, June 21, 2023
Ulcerative colitis, Webcast, Roivant Sciences, Cryptocurrency, Online shopping, Mobile phone

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 (anti-TL1A antibody) in ulcerative colitis.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 (anti-TL1A antibody) in ulcerative colitis.
  • To access the call by phone, please register online using this registration link .
  • A webcast of the call will also be available under “Events & Presentations” in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events.
  • The archived webcast will be available on Roivant’s website after the call.

ESSA Pharma Appoints Lauren Merendino to its Board of Directors

Retrieved on: 
Tuesday, June 6, 2023
EPIX, Chief commercial officer, Pennsylvania State University, N, Genentech, Lauren, Government, ESSA, SAN, Roivant Sciences, Commercial, Prostate cancer, Pharmaceutical industry, Microbiology, New York University, Marketing

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors.

Key Points: 
  • SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors.
  • Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.
  • "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the skillset of our Board of Directors," stated Richard M. Glickman, L.L.D.
  • (Hon), Chairman of ESSA's Board of Directors.

CareRev Announces the Appointment of Brandon Atkinson as Chief Executive Officer and Expanded Leadership Team

Retrieved on: 
Friday, June 2, 2023
Vista Equity Partners, Amazon Web Services, Travel, University, Public affairs, LBJ School, Monetate, University of Texas at Austin, History, Roivant Sciences, Rutgers University, Lyft, Atkinson, Tableau, Hospital, Patient, Machine learning, Growth, Opsware, AppNexus, Management, SoftBank Group, Amazon, Apple, Accolade, Salesforce

VENICE, Calif., June 2, 2023 /PRNewswire/ -- CareRev, a technology platform for healthcare workforce optimization, today announced that Brandon Atkinson has been named chief executive officer.

Key Points: 
  • VENICE, Calif., June 2, 2023 /PRNewswire/ -- CareRev, a technology platform for healthcare workforce optimization, today announced that Brandon Atkinson has been named chief executive officer.
  • In addition to Atkinson's appointment, CareRev made several executive leadership hires in the last eight months as part of the company's strategic growth initiatives.
  • Patty Bedard , chief people officer, joined from Amazon where she was head of executive development.
  • Ash Upreti joined CareRev as chief legal officer, previously having served as legal counsel at Optimus Ride, Lyft and Apple.

Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids

Retrieved on: 
Wednesday, May 17, 2023
Wearables, Mobile Technology, Technology, Women, Health Technology, Software, Consumer, Health, Data Management, Science, Other Science, Endometriosis, Pelvic inflammatory disease, Life, Education, Workplace, Absenteeism, Dysmenorrhea, Statistics, Innovation, Multimedia, Cycle, Interface (computing), Meigs's syndrome, Roivant Sciences, Uterine fibroid, Fibroid, Menstrual cycle, Diagnosis, Entrepreneurship, Ageing, Uterine cancer, Primary ovarian insufficiency, Ovarian cancer, Environment, Female, Nursing, Management, Medical device, Medical imaging, Birth control, Evidence-based policy

Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.

Key Points: 
  • Today, as part of National Women’s Health Week, Evidation and Myovant Sciences Ltd. (“Myovant”), a wholly owned subsidiary of Sumitovant Biopharma Ltd. (“Sumitovant”) announced results from a survey exploring the lived experiences of individuals with endometriosis and/or uterine fibroids.
  • View the full release here: https://www.businesswire.com/news/home/20230517005194/en/
    “At Myovant, we know that stigma can often keep people quiet about periods, leading to delayed care and increased discomfort.
  • It also contributes to the lack of awareness about how conditions such as endometriosis and uterine fibroids can increase absenteeism and impact performance at work and school,” said Kalahn Taylor-Clark, vice president and head of Strategic Partnerships and Innovation at Myovant Sciences.
  • The survey covered four areas, including demographics, menstrual history and health, experiences at work or school, and experiences with medical providers.

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, May 4, 2023
Communication, Arm, Therapy, Virology, Coronavirus, COVID-19, NA, Tax, Viral, Roivant Sciences, Research, RNA, CFBV, HBsAg, Tokyo International Conference on African Development, Antiviral Research, Patient, Investment, Immune system, RNA interference, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, HBV, Conference, Food, Safety, Nivolumab, Vaccine, Pharmaceutical industry, Cryptocurrency, Arbutus

Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161

Key Points: 
  • Dosed first subject in Phase 1 clinical trial with oral RNA Destabilizer, AB-161
    WARMINSTER, Pa., May 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reported first quarter 2023 financial results and provided a corporate update.
  • “In the first quarter of 2023, we made meaningful progress advancing our pipeline of HBV and coronavirus assets to address large global market opportunities,” said William Collier, Arbutus’ President and Chief Executive Officer.
  • We expect to announce preliminary data from patients receiving the combination of AB-729, NA therapy and IFN in the second quarter of 2023.
  • Roivant Sciences Ltd. owned approximately 23% of our outstanding common shares as of March 31, 2023.

EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms

Retrieved on: 
Wednesday, May 3, 2023
Diamond, Insurance, BB Biotech, Drug development, University, Depression, Therapy, Roche, Cancer, Intelligence, Roivant Sciences, Research, Biomarker, Antibody, University of Geneva, MS, Patient, Risk, Machine learning, Algorithm, Drug discovery, Artificial intelligence, AI, FGFR2, Epidemiology, Neurology, News, Peptide, Data science, Pharmaceutical industry, Cryptocurrency, Biochemistry

Artificial intelligence and machine-learning algorithms are disruptive technologies that are having a two-fold impact on the drug discovery process.

Key Points: 
  • Artificial intelligence and machine-learning algorithms are disruptive technologies that are having a two-fold impact on the drug discovery process.
  • Over the past few years BB Biotech has integrated huge volumes of datasets into its own IT infrastructure, covering a wide range of data types.
  • As for the types of drug classes studied, traditional small molecule drugs clearly predominate, followed by biologics (antibodies and peptides).
  • BB Biotech will be closely monitoring developments in the field of computational biotech during the coming years.